Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Nobuyoshi Arima, Fumiaki Nakamura, Toshio Yabe, Junji Tanaka, Shigeo Fuji, Kazuteru Ohashi, Takahiro Fukuda, Koichi Miyamura, Koji Iwato, Tetsuya Eto, Takehiko Mori, Naoki Kobayashi, Takumi Hoshino, Chiaki Kato, Heiwa Kanamori, Hirohisa Nakamae, Yoshiko Atsuta, Yasuo Morishima, Yoshinobu Kanda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Licensing by self MHC class I ligands is required for proper natural killer (NK) cell response. NK cells with inhibitory killer cell immunoglobulin-like receptors for nonself MHC exhibit transient alloreactivity after hematopoietic stem cell transplantation (HSCT). We analyzed 3866 recipients in the Japan national registry who underwent their first allogeneic HSCT for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) from HLA-A, -B, and -DRB1 allele-genomatched unrelated donors. By classifying them into 5 independent groups based on HLA-C group matching and assumed donor NK cell status, we found that for HLA-C-matched HSCT for AML in HLA-C1/C1 recipients, in whom transient alloreactivity against HLA-C2-negative leukemic cells was expected, the relapse rate was significantly lower than it was in HLA-C-matched HSCT for AML in HLA-C1/C2 recipients (hazard ratio [HR], .72; P = .011). This difference was not observed in HLA-C-matched HSCT for ALL. Compared with HLA-C-matched HSCT, significantly higher mortality was observed in HLA-C1/C1 AML patients who received transplants from HLA-C-mismatched HLA-C1/C1 donors (HR, 1.37; P = .001) and in HLA-C1/C1 ALL patients who received transplants from HLA-C2-positive donors (HR, 2.13; P = .005). In conclusion, donor selection based on leukemic subtype and donor HLA-C group matching improves transplantation outcome after HLA-C-mismatched HSCT.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2015 Jul 26

Fingerprint

HLA-C Antigens
Hematopoietic Stem Cell Transplantation
Natural Killer Cells
Registries
Leukemia
Transplants
Acute Myeloid Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tissue Donors
KIR Receptors
Donor Selection
Unrelated Donors
HLA-A Antigens
HLA-B Antigens
Transplant Recipients
Licensure
Japan
Transplantation
Alleles
Ligands

Keywords

  • Acute leukemia
  • Allogeneic hematopoietic stem cell transplantation
  • HLA-C mismatch
  • Killer cell immunoglobulin-like receptor
  • Natural killer cell

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia : A Japanese National Registry Study. / Arima, Nobuyoshi; Nakamura, Fumiaki; Yabe, Toshio; Tanaka, Junji; Fuji, Shigeo; Ohashi, Kazuteru; Fukuda, Takahiro; Miyamura, Koichi; Iwato, Koji; Eto, Tetsuya; Mori, Takehiko; Kobayashi, Naoki; Hoshino, Takumi; Kato, Chiaki; Kanamori, Heiwa; Nakamae, Hirohisa; Atsuta, Yoshiko; Morishima, Yasuo; Kanda, Yoshinobu.

In: Biology of Blood and Marrow Transplantation, 26.07.2015.

Research output: Contribution to journalArticle

Arima, N, Nakamura, F, Yabe, T, Tanaka, J, Fuji, S, Ohashi, K, Fukuda, T, Miyamura, K, Iwato, K, Eto, T, Mori, T, Kobayashi, N, Hoshino, T, Kato, C, Kanamori, H, Nakamae, H, Atsuta, Y, Morishima, Y & Kanda, Y 2015, 'Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2015.09.029
Arima, Nobuyoshi ; Nakamura, Fumiaki ; Yabe, Toshio ; Tanaka, Junji ; Fuji, Shigeo ; Ohashi, Kazuteru ; Fukuda, Takahiro ; Miyamura, Koichi ; Iwato, Koji ; Eto, Tetsuya ; Mori, Takehiko ; Kobayashi, Naoki ; Hoshino, Takumi ; Kato, Chiaki ; Kanamori, Heiwa ; Nakamae, Hirohisa ; Atsuta, Yoshiko ; Morishima, Yasuo ; Kanda, Yoshinobu. / Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia : A Japanese National Registry Study. In: Biology of Blood and Marrow Transplantation. 2015.
@article{7a00f4ff88204bde8c4f9b1534e05f0a,
title = "Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study",
abstract = "Licensing by self MHC class I ligands is required for proper natural killer (NK) cell response. NK cells with inhibitory killer cell immunoglobulin-like receptors for nonself MHC exhibit transient alloreactivity after hematopoietic stem cell transplantation (HSCT). We analyzed 3866 recipients in the Japan national registry who underwent their first allogeneic HSCT for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) from HLA-A, -B, and -DRB1 allele-genomatched unrelated donors. By classifying them into 5 independent groups based on HLA-C group matching and assumed donor NK cell status, we found that for HLA-C-matched HSCT for AML in HLA-C1/C1 recipients, in whom transient alloreactivity against HLA-C2-negative leukemic cells was expected, the relapse rate was significantly lower than it was in HLA-C-matched HSCT for AML in HLA-C1/C2 recipients (hazard ratio [HR], .72; P = .011). This difference was not observed in HLA-C-matched HSCT for ALL. Compared with HLA-C-matched HSCT, significantly higher mortality was observed in HLA-C1/C1 AML patients who received transplants from HLA-C-mismatched HLA-C1/C1 donors (HR, 1.37; P = .001) and in HLA-C1/C1 ALL patients who received transplants from HLA-C2-positive donors (HR, 2.13; P = .005). In conclusion, donor selection based on leukemic subtype and donor HLA-C group matching improves transplantation outcome after HLA-C-mismatched HSCT.",
keywords = "Acute leukemia, Allogeneic hematopoietic stem cell transplantation, HLA-C mismatch, Killer cell immunoglobulin-like receptor, Natural killer cell",
author = "Nobuyoshi Arima and Fumiaki Nakamura and Toshio Yabe and Junji Tanaka and Shigeo Fuji and Kazuteru Ohashi and Takahiro Fukuda and Koichi Miyamura and Koji Iwato and Tetsuya Eto and Takehiko Mori and Naoki Kobayashi and Takumi Hoshino and Chiaki Kato and Heiwa Kanamori and Hirohisa Nakamae and Yoshiko Atsuta and Yasuo Morishima and Yoshinobu Kanda",
year = "2015",
month = "7",
day = "26",
doi = "10.1016/j.bbmt.2015.09.029",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia

T2 - A Japanese National Registry Study

AU - Arima, Nobuyoshi

AU - Nakamura, Fumiaki

AU - Yabe, Toshio

AU - Tanaka, Junji

AU - Fuji, Shigeo

AU - Ohashi, Kazuteru

AU - Fukuda, Takahiro

AU - Miyamura, Koichi

AU - Iwato, Koji

AU - Eto, Tetsuya

AU - Mori, Takehiko

AU - Kobayashi, Naoki

AU - Hoshino, Takumi

AU - Kato, Chiaki

AU - Kanamori, Heiwa

AU - Nakamae, Hirohisa

AU - Atsuta, Yoshiko

AU - Morishima, Yasuo

AU - Kanda, Yoshinobu

PY - 2015/7/26

Y1 - 2015/7/26

N2 - Licensing by self MHC class I ligands is required for proper natural killer (NK) cell response. NK cells with inhibitory killer cell immunoglobulin-like receptors for nonself MHC exhibit transient alloreactivity after hematopoietic stem cell transplantation (HSCT). We analyzed 3866 recipients in the Japan national registry who underwent their first allogeneic HSCT for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) from HLA-A, -B, and -DRB1 allele-genomatched unrelated donors. By classifying them into 5 independent groups based on HLA-C group matching and assumed donor NK cell status, we found that for HLA-C-matched HSCT for AML in HLA-C1/C1 recipients, in whom transient alloreactivity against HLA-C2-negative leukemic cells was expected, the relapse rate was significantly lower than it was in HLA-C-matched HSCT for AML in HLA-C1/C2 recipients (hazard ratio [HR], .72; P = .011). This difference was not observed in HLA-C-matched HSCT for ALL. Compared with HLA-C-matched HSCT, significantly higher mortality was observed in HLA-C1/C1 AML patients who received transplants from HLA-C-mismatched HLA-C1/C1 donors (HR, 1.37; P = .001) and in HLA-C1/C1 ALL patients who received transplants from HLA-C2-positive donors (HR, 2.13; P = .005). In conclusion, donor selection based on leukemic subtype and donor HLA-C group matching improves transplantation outcome after HLA-C-mismatched HSCT.

AB - Licensing by self MHC class I ligands is required for proper natural killer (NK) cell response. NK cells with inhibitory killer cell immunoglobulin-like receptors for nonself MHC exhibit transient alloreactivity after hematopoietic stem cell transplantation (HSCT). We analyzed 3866 recipients in the Japan national registry who underwent their first allogeneic HSCT for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) from HLA-A, -B, and -DRB1 allele-genomatched unrelated donors. By classifying them into 5 independent groups based on HLA-C group matching and assumed donor NK cell status, we found that for HLA-C-matched HSCT for AML in HLA-C1/C1 recipients, in whom transient alloreactivity against HLA-C2-negative leukemic cells was expected, the relapse rate was significantly lower than it was in HLA-C-matched HSCT for AML in HLA-C1/C2 recipients (hazard ratio [HR], .72; P = .011). This difference was not observed in HLA-C-matched HSCT for ALL. Compared with HLA-C-matched HSCT, significantly higher mortality was observed in HLA-C1/C1 AML patients who received transplants from HLA-C-mismatched HLA-C1/C1 donors (HR, 1.37; P = .001) and in HLA-C1/C1 ALL patients who received transplants from HLA-C2-positive donors (HR, 2.13; P = .005). In conclusion, donor selection based on leukemic subtype and donor HLA-C group matching improves transplantation outcome after HLA-C-mismatched HSCT.

KW - Acute leukemia

KW - Allogeneic hematopoietic stem cell transplantation

KW - HLA-C mismatch

KW - Killer cell immunoglobulin-like receptor

KW - Natural killer cell

UR - http://www.scopus.com/inward/record.url?scp=84949257524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949257524&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.09.029

DO - 10.1016/j.bbmt.2015.09.029

M3 - Article

C2 - 26456260

AN - SCOPUS:84949257524

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -